Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-10-31Clinical Trial Update: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration [Phase 2]
Phase 2 trial of multiple-dose intravitreal GEM103 for neovascular age-related macular degeneration was terminated, with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD [Phase 2]
Phase 2 trial evaluating AKST4290 in combination with aflibercept for neovascular age-related macular degeneration has completed with result…
-
FDA approval · 2022-08-15FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approves Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, authorizing the biosimilar for the same ocular indications …
-
FDA approval · 2022-06-09FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) [Phase 3]
The TENAYA Phase 3 trial evaluating faricimab for neovascular age-related macular degeneration has completed and posted results in 2022, rep…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) [Phase 3]
Phase 3 LUCERNE trial evaluated the efficacy and safety of Faricimab in neovascular age-related macular degeneration; results were posted in…
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: SD-OCT Angiography [NA]
Clinical trial update for SD-OCT Angiography study (NCT02510885) sponsored by Duke University; the trial is terminated, with results posted …
-
FDA approval · 2022-04-18FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for SUSVIMO, Genentech's port delivery system for ranibizumab, expanding its use for the treatme…
-
CLINICAL_TRIALS trial_result · 2022-03-25Clinical Trial Update: A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration [Phase 3]
Phase III study evaluating the Port Delivery System with ranibizumab versus monthly injections for wet age-related macular degeneration has …
-
FDA approval · 2022-03-09FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BEOVU (brolucizumab) from Novartis Pharmaceuticals Corporation, resulting in an updated labe…
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) [Phase 2]
Phase 2 trial evaluating ZIMURA in combination with LUCENTIS for neovascular age-related macular degeneration has completed, with results po…
-
FDA approval · 2022-01-28FDA Approved: VABYSMO — Original Application (Genentech, Inc.)
FDA approves VABYSMO (faricimab) for the treatment of neovascular age-related macular degeneration and diabetic macular edema under the orig…
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD [Phase 2]
Phase 2 trial comparing a depot formulation of sunitinib malate (GB-102) versus aflibercept in neovascular AMD has completed with posted res…
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept [Phase 4]
Clinical trial update for intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept; st…
-
FDA approval · 2021-09-17FDA Approved: BYOOVIZ — Original Application (BIOGEN INC.)
BYOOVIZ, Biogen's ranibizumab-nuna biosimilar, has been approved by the FDA through its Original Application, with indications matching thos…
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) [Phase 3]
Phase 3 trial of intravitreal conbercept for neovascular age-related macular degeneration was terminated.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) [Phase 3]
Phase 3 trial of intravitreal conbercept for neovascular age-related macular degeneration was terminated.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration [Phase 3]
APhase 3 trial evaluating CKD-701 and Lucentis in neovascular (wet) age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 3]
Phase 3 trial update comparing two aflibercept regimens in neovascular age-related macular degeneration completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD [Phase 2]
Phase 2 dose-ranging study of OPT-302 with ranibizumab in neovascular age-related macular degeneration completed.
-
CLINICAL_TRIALS trial_result · 2021-01-05Clinical Trial Update: Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration [Phase 2]
Phase 2 trial update evaluating faricimab for extended durability in neovascular age-related macular degeneration (nAMD) has completed with …
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial update on intravitreal LFG316 for wet age-related macular degeneration showing safety and efficacy data.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Safety and Tolerability Study for Age-Related Macular Degeneration [Phase 1, Phase 2]
A completed Phase 1/2 safety and tolerability study for neovascular age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) [Phase 1, Phase 2]
Phase 1/2 trial update evaluating safety and efficacy of AS101 1% oral solution in neovascular age-related macular degeneration has complete…
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial of intravitreal REGN2176-3 for neovascular age-related macular degeneration was terminated with results posted in 2020.